X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2022 Earnings Conference Call March 21, 2023 9:00 AM ET

Company Participants

Dan Ferry - IR, LifeSci Advisors

Paula Ragan - CEO

Adam Mostafa - CFO

Murray Stewart - Interim Chief Medical Officer

Mark Baldry - Chief Commercial Officer

Conference Call Participants

Divya Rao - TD Cowen

Edward Tenthoff - Piper Sandler

Kristen Kluska - Cantor Fitzgerald

Swayampakula Ramakanth - H.C. Wainwright

Operator

Thank you for standing by. This is the conference operator. Welcome to X4 Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Conference Call. As a reminder, all participants are in listen-only mode, and the conference is being recorded. After the presentation there’ll be an opportunity to ask questions [Operator Instructions].

It's now my pleasure to introduce your host, Dan Ferry from LifeSci Advisors. Please go ahead.

Dan Ferry

Thank you, operator. And good morning, everyone. Presenting on today's call will be X4's Chief Executive Officer Dr. Paula Ragan and Chief Financial Officer, Adam Mostafa. Following prepared remarks, we will open the call to your questions and will be joined by, Interim Chief Medical Officer, Dr. Murray Stewart, Chief Commercial Officer, Mark Baldry, Chief Scientific Officer, Dr. Art Taveras, and Chief Operating Officer, Dr. Mary DiBiase.

As a reminder on today's call, the company will be making forward-looking statements regarding regulatory and product development plans as well as research activities. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in X4's filings with the SEC from time to time, including this Company’s latest 10-Q filling on November 3 2022 and in the 10-K for 2022, which is expected to be filed after market close today.

I'd now like to turn the call over to X4's President and CEO Dr. Paula Ragan. Paula?

Paula Ragan

Thanks, Dan. And thank you everyone for joining us on the call. As we mentioned in the press release this morning, we could not be more pleased with the progress we made in 2022, advancing our lead candidate, mavorixafor towards commercialization, and most importantly, towards helping patients in need.

We believe our clinical trial data continue to speak volumes, unequivocally demonstrating mavorixafor’s ability to chronically raise circulating levels of neutrophils, lymphocytes and monocytes.

As you may be aware, following our strategic announcement last July, when we tightened our focus to advance mavorixafor in chronic neutropenic disorders, we achieved two significant development milestones, announcing positive clinical results from both our Pivotal Phase 3 trial of mavorixafor in WHIM syndrome and our Phase 1b clinical trial of mavorixafor in certain chronic neutropenic disorders.